Abstract:One characteristic feature of Alzheimer's disease (AD) neuropathology is the progressive generation, aggregation and deposition of the 42 amino acid amyloid beta (Aβ42) peptide, and other related amyloidogenic molecules, into dense clumps of insoluble, pro-inflammatory senile plaque cores in the extracellular space of the brain. It is not generally appreciated that the Aβ42 peptide, derived via tandem beta-gamma secretase cleavage of the larger ~770 amino acid transmembrane beta-amyloid precursor protein (βAPP) is one of the “stickiest” peptides known, due in part to its high content of lipophillic and hydrophobic peptide domains (21.4% valine-isoleucine; Mager, 1998; Watson et al., 2005). Aβ42 peptide monomers have tremendously high potential for relatively rapid self-aggregation into Aβ42 peptide dimers and higher order fibrillar structures via long-range, non-covalent hydrophobic forces that over time promote β-pleated sheet conformations (Mager, 1998; Watson et al., 2005; Boutajangout and Wisniewski, 2013; Chang et al., 2013). There is abundant evidence that under normal, homeostatic conditions, Aβ42 peptide monomers and perhaps other higher order Aβ42 peptides are effectively “cleared” from the brain's extracellular medium by highly active and efficient innate-immune surveillance and phagocytic systems that limit excessive Aβ42 peptide dimerization, accumulation and further self-aggregation into pathological senile plaque lesions. Recently described, one of the key phagocytosis sensor-receptors responsible for Aβ42 peptide clearance from the human central nervous system (CNS) is very likely the triggering receptor expressed in myeloid/microglial cells 2 (TREM2) enriched in myeloid cells and microglial cells of the CNS (Benitez et al., 2013; Forabosco et al., 2013; Gonzalez Murcia et al., 2013; Guerreiro et al., 2013; Neumann and Daly, 2013; Zhao et al., 2013; Jones et al., 2014; Figure Figure1).1). This short paper is an update on some very recent observations on TREM2 neurobiology, on newly discovered roles for miRNA-34a-mediated signaling in human degenerative disease, including miRNA-34a-mediated effects on TREM2 expression, and how dysfunctional TREM2 signaling may contribute to amyloidogenesis in AD and in related progressive, inflammatory neurodegenerative diseases of the human CNS.

Microglia, Trem2, and Neurodegeneration

TREM2-Dependent Effects on Microglia in Alzheimer's Disease

TREM2 in Alzheimer's Disease: Microglial Survival and Energy Metabolism.

The role of microglial TREM2 in development: A path toward neurodegeneration?

Opposing Roles of the Triggering Receptor Expressed on Myeloid Cells 2 and Triggering Receptor Expressed on Myeloid Cells-Like Transcript 2 in Microglia Activation.

TREM1 Facilitates Microglial Phagocytosis of Amyloid Beta

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

Deficits in the Mirna-34A-regulated Endogenous TREM2 Phagocytosis Sensor-Receptor in Alzheimer's Disease (AD); an Update.

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

TREM2 signalling as a multifaceted player in brain homoeostasis and a potential target for Alzheimer's disease treatment

Gene expression and functional deficits underlie TREM2-knockout microglia responses in human models of Alzheimer’s disease

Elevating Microglia TREM2 Reduces Amyloid Seeding and Suppresses Disease-Associated Microglia

The Challenges of Modulating Neuroinflammation in Alzheimer's Disease and Multiple Sclerosis with TREM2 Agonistic Antibodies

TREM2 in CNS Homeostasis and Neurodegenerative Disease

The Pathogenesis in Alzheimer's Disease: TREM2 as a Potential Target

The Specific Mechanism of TREM2 Regulation of Synaptic Clearance in Alzheimer's Disease

Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2

Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer’s and related dementias

The Emerging Roles and Therapeutic Potential of Soluble TREM2 in Alzheimer's Disease.

TREM2 is a Receptor for Β-Amyloid That Mediates Microglial Function

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways